New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
05:52 EDTAMPEAmpio initiates clinical trial of Optina in DME, first patient dosed
Ampio Pharmaceuticals announced oral dosing of the first patient in a 505b2 clinical trial of the investigational drug Optina in diabetic macular edema, or DME. The trial will evaluate Optina in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina 505b2 status and drugs designated under this pathway can be approved on a single trial.
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2015
09:13 EDTAMPEAmpio to host conference call
Conference call to discuss Ampio's distribution to its existing stockholders of shares of common stock of Aytu BioScience, Inc, as well as Aytu's current business plans will be held on November 19 at 4:15 pm. Webcast Link
November 17, 2015
08:33 EDTAMPEAmpio to distribute shares of Aytu BioSciences to its stockholders
Ampio Pharmaceuticals announced it has established a record date of December 1 for its previously announced distribution to its stockholders of its shares of Common Stock of Aytu BioSciences. Ampio will distribute one share of Aytu common stock for every five shares of Ampio Common Stock owned as of the record date. This distribution will constitute over 70% of the Aytu shares outstanding at this time and approximately 90% of the Aytu shares owned by Ampio. The distribution date is expected to be January 4, 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use